New Risk Landscape for Generic Pharmaceutical Companies
As the generic pharmaceutical industry evolves along several fronts, it faces numerous challenges and opportunities: slowing growth rates, healthcare pressures regarding cost inflation, regulatory labeling efforts, an emerging biosimilar market, mega merger activity, and a need to seek generic avenues for high-priced specialty drug alternatives. These changes create a new risk environment.
Jeff Peck and Joe Thomas from Ulmer & Bernie LLP joined Marsh’s Life Sciences risk leaders, Doug Carey, Etet Deguia and Darlene Villoresi, to discuss the how the insurance industry is responding to the Food and Drug Administration’s (FDA) proposed labeling changes. This 45-minute complimentary replay also provides an update on the generic products liability insurance market environment.